Literature DB >> 14986014

Glucocorticoid use represents a risk factor for central serous chorioretinopathy: a prospective, case-control study.

Panagiotis Karadimas1, Evrydiki A Bouzas.   

Abstract

PURPOSE: To evaluate whether exposure to glucocorticoids represents a risk factor for the development of central serous chorioretinopathy (CSCR).
METHODS: Prospective, case-control study. Thirty-eight consecutive patients with acute CSCR were asked to answer a specific questionnaire regarding the use of glucocorticoids, in any form, during the last month before the onset of the symptoms. An age- and sex-matched control group was also recruited. It consisted of patients attending the outpatient department for a condition other than CSCR, who were asked to answer the same questionnaire.
RESULTS: Use of glucocorticoids was recorded in 11 of 38 patients (28.9%) with CSCR; 8 of them were men and 3 women. In the control group, use of glucocorticoids was recorded in 2 of 38 patients (5.2%), 1 man and 1 woman. The difference between the two groups is statistically significant (odds ratio=7.33, 95% CI=1.49-35.85, P=0.006).
CONCLUSION: In this prospective, case-control study, we found that glucocorticoid use represents a risk factor for the development of CSCR.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14986014     DOI: 10.1007/s00417-004-0885-z

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  9 in total

Review 1.  Central serous chorioretinopathy and glucocorticoids.

Authors:  Evrydiki A Bouzas; Panagiotis Karadimas; Constantin J Pournaras
Journal:  Surv Ophthalmol       Date:  2002 Sep-Oct       Impact factor: 6.048

2.  Maculopathy a corticosteroid side-effect.

Authors:  I S Jain; K Singh
Journal:  J All India Ophthalmol Soc       Date:  1966-12

3.  Corticosteroid-induced central serous chorioretinopathy.

Authors:  M Wakakura; E Song; S Ishikawa
Journal:  Jpn J Ophthalmol       Date:  1997 May-Jun       Impact factor: 2.447

4.  Systemic findings associated with central serous chorioretinopathy.

Authors:  M K Tittl; R F Spaide; D Wong; E Pilotto; L A Yannuzzi; Y L Fisher; B Freund; D R Guyer; J S Slakter; J A Sorenson
Journal:  Am J Ophthalmol       Date:  1999-07       Impact factor: 5.258

5.  Central serous chorioretinopathy complicating systemic corticosteroid treatment.

Authors:  M Wakakura; S Ishikawa
Journal:  Br J Ophthalmol       Date:  1984-05       Impact factor: 4.638

6.  Membranoproliferative glomerulonephritis type II associated with central serous retinopathy.

Authors:  M R Ulbig; P Riordan-Eva; F G Holz; H C Rees; P A Hamilton
Journal:  Am J Ophthalmol       Date:  1993-10-15       Impact factor: 5.258

7.  Central serous chorioretinopathy in endogenous hypercortisolism.

Authors:  E A Bouzas; M H Scott; G Mastorakos; G P Chrousos; M I Kaiser-Kupfer
Journal:  Arch Ophthalmol       Date:  1993-09

8.  Corticosteroids and central serous chorioretinopathy.

Authors:  Cynthia A Carvalho-Recchia; Lawrence A Yannuzzi; Silvana Negrão; Richard F Spaide; K Bailey Freund; Hanna Rodriguez-Coleman; Marcio Lenharo; Tomohiro Iida
Journal:  Ophthalmology       Date:  2002-10       Impact factor: 12.079

9.  Macular and paramacular detachment of the neurosensory retina associated with systemic diseases.

Authors:  C Y Lowder; F A Gutman; H Zegarra; Z N Zakov; J N Lowder; J D Clough
Journal:  Trans Am Ophthalmol Soc       Date:  1981
  9 in total
  13 in total

Review 1.  Central serous chorioretinopathy: update on pathophysiology and treatment.

Authors:  Benjamin Nicholson; Jason Noble; Farzin Forooghian; Catherine Meyerle
Journal:  Surv Ophthalmol       Date:  2013 Mar-Apr       Impact factor: 6.048

2.  Corticosteroids usage and central serous chorioretinopathy: a meta-analysis.

Authors:  Ge Ge; Yun Zhang; Yichi Zhang; Zhihui Xu; Meixia Zhang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-11-16       Impact factor: 3.117

3.  Exacerbation of central serous chorioretinopathy following intravitreal triamcinolone injection.

Authors:  M Selim Kocabora; Sahan Durmaz; Nilay Kandemir
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-09-03       Impact factor: 3.117

4.  Epidemiology of idiopathic central serous chorioretinopathy in Taiwan, 2001-2006: a population-based study.

Authors:  Der-Chong Tsai; Shih-Jen Chen; Chin-Chou Huang; Pesus Chou; Chia-Min Chung; Po-Hsun Huang; Shing-Jong Lin; Jaw-Wen Chen; Tseng-Ji Chen; Hsin-Bang Leu; Wan-Leong Chan
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

5.  Indocyanine green angiography in chronic central serous chorioretinopathy.

Authors:  Urszula Gajdzik-Gajdecka; Mariola Dorecka; Ewa Nita; Anna Michalska; Joanna Miniewicz-Kurowska; Wanda Romaniuk
Journal:  Med Sci Monit       Date:  2012-02

6.  Forgotten exogenous corticosteroid as a cause of central serous chorioretinopathy.

Authors:  Paul W Hardwig; Amila O Silva; Jose S Pulido
Journal:  Clin Ophthalmol       Date:  2008-03

7.  Association between Central Serous Chorioretinopathy and Risk of Depression: A Population-Based Cohort Study.

Authors:  Yu-Yen Chen; Li-Ying Huang; Wei-Ling Liao; Pesus Chou
Journal:  J Ophthalmol       Date:  2019-05-02       Impact factor: 1.909

8.  Ciliochoroidal effusion syndrome with central serous-like chorioretinopathy and secondary angle closure following exogenous testosterone use.

Authors:  Daniel Brill; Desiree Albert; Taylor Fields; Shravani Mikkilineni; David Crandall; Hua Gao
Journal:  Am J Ophthalmol Case Rep       Date:  2019-06-05

9.  Central serous chorioretinopathy and systemic corticosteroids in rheumatic diseases: report of three cases.

Authors:  Elia Valls Pascual; Lucía Martínez-Costa; Fernando Santander
Journal:  BMC Musculoskelet Disord       Date:  2015-12-05       Impact factor: 2.362

Review 10.  The Role of Alpha-MSH as a Modulator of Ocular Immunobiology Exemplifies Mechanistic Differences between Melanocortins and Steroids.

Authors:  Christine M Clemson; John Yost; Andrew W Taylor
Journal:  Ocul Immunol Inflamm       Date:  2016-01-25       Impact factor: 3.070

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.